Alrizomadlin (AA-115; APG-115; AA115; APG115) is a novel, potent, orally bioactive and efficacious MDM2-p53 inhibitor with the potential to be used for the treatment of relapsed/refractory unresectable or metastatic melanoma. It is being investigated in clinical trials for cancer treatment. As of September 23, 2021, Alrizomadlin has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to prior immune-oncologic agents, according to a press release by Ascentage Pharma. AA-115 has a very high affinity to MDM2 (Ki < 1 nM), potent cellular activity, and an excellent orally bioavailable pharmacokinetic profile. Compound 60 is capable of achieving complete and longlasting tumor regression in vivo and is currently in phase I clinical trials for cancer treatment.

纯度：≥98%

CAS：1818393-16-6